Summary
Early estimates of the economic consequences of cimetidine use indicated a cost reduction for the healthcare system and for society. A Swedish study based on registry data between 1973 and 1983 showed a net economic gain because the reduction in indirect costs (a decline in disability pensions and short term absence from work) exceeded the increase in direct costs. However, the increase in total costs for ulcer drugs at the time of introduction of cimetidine was higher than the reduction in costs due to a concurrent decrease in the number of major elective surgical interventions for peptic ulcer.
Recent data show that the costs for drugs used in the treatment of peptic ulcer continue to grow. The total costs for drugs increased in fixed prices 3 times between 1984 and 1993, while the use of inpatient care and surgical interventions decreased. In 1981, the total number of major operations for gastric or duodenal ulcer in Sweden was 21.6 per 100 000 inhabitants. In 1991, the comparable figure was 6.3 operations. At the same time, the number of inpatient days was reduced by 30% because of shorter periods of hospitalisation, while the number of hospital admissions with peptic ulcer as the main diagnosis increased, especially in groups aged over 75 years. In younger age groups, the admission rate has been slightly reduced. The savings in hospital care as a result of fewer operations are probably small compared with the increased costs for drugs. The effect on other supplementary drugs (e.g. antacids), ambulatory care, and indirect costs has to be studied before conclusions can be drawn regarding the total effect of the introduction of new drugs in the treatment of peptic ulcer after 1983.
Similar content being viewed by others
References
Bardhan KD, Naesdal J, Bianchi Porro G, et al. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. Gut 32: 435–438, 1991
Bodemar G, Walan A. Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet 1: 403–408, 1978
Carlsson P. Spridning och ekonomiska effekter av medicinsk teknologi — vid behandling av magsar, prostataforstoring och gallsten. (Diffusion and economic effects of medical technology — in treatment of peptic ulcer, prostatic hyperplasia and gallbladder disease.) Linkoping Studies in Arts and Science No. 12 (Diss.), Linkoping University, 1987
Culyer AJ, Maynard AK. Cost-effectiveness of duodenal ulcer treatment. Social Science of Medicine 15c: 3–11, 1981
Farbrot T, Farbrot E. Effekt av cimetidine behandling pa syke-medling og hospitalisering. Tidskrift for den Norske Laegetorening 104: 595–596, 1984
Fineberg HV, Pearlman LA. Benefit-and-cost analysis of medical interventions: the case of cimetidine and peptic ulcer disease. Office of Technology Assessment, case study 11, Washington, 1981
Gustavsson S, Kelly KA, Melton LJ, Zinsmeister AR. Trends in peptic ulcer surgery. Gastroenterology 94: 688–694, 1988
Gustavsson S, Nyren O. Stadig minskning av operationer for ventrikel- och duodenalsar. Swedish Journal of Medicine 86: 3357–3361, 1989
Horisberger B. A review of the epidemiological development of peptic ulcers and an evaluation of duodenal ulcers in Federal Republic of Germany before and after cimetidine. In Gulyer AJ & Horisberger (Eds) Economic and medical evaluation of health care technologies, pp. 213–236, Springer Verlag, Berlin, 1983
Jonsson B. A review of the macroeconomic evaluation of cimetidine. In Culyer & Horisberger (Eds) Economic and medical evaluation of health care technologies, pp. 243–261, Springer Verlag, Berlin, 1983
Jonsson B, Carlsson P. The effects of cimetidine on the cost of ulcer disease in Sweden. Social Science of Medicine 33: 275–282, 1991
Kurata JH, Corboy ED. Current peptic ulcer time trends: an epidemiological profile. Journal of Clinical Gastroenterology 10: 259–268, 1988
Strom M, Bodemar G, Lindhagen J, et al. Sick-listing following parietal-cell vagotomy and during long-term treatment with cimetidine. In Strom M (Ed.) Cimetidine and parietal-cell vagotomy in severe juxtapyloric ulcer disease — a randomized trial, Linkoping University Medical Dissertations No. 234, 1984
Walan A, Strom M. Prevention of ulcer recurrences — medical vs surgical treatment. The physician’s view. Scandinavian Journal of Gastroenterology 20 (Suppl. 100): 83–88, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carlsson, P. New Drug Introductions and the Cost of Ulcer in Sweden. Pharmacoeconomics 5 (Suppl 3), 8–16 (1994). https://doi.org/10.2165/00019053-199400053-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199400053-00004